Repository logo
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
Repository logo
    Communities & Collections
    Research Outputs
    Fundings & Projects
    People
    Organizations
    Statistics
  • English
  • 中文
  • Log In
    New user? Click here to register.Have you forgotten your password?
  1. Home
  2. College of Medical Science and Technology/醫學科技學院
  3. Department of Medical Imaging and Radiological Sciences/醫學影像暨放射科學系
  4. 利用磁振造影T1權重影像比較健康人、輕度認知障礙、阿茲海默症病人之藍斑核對比度差異
 
  • Details
Options

利用磁振造影T1權重影像比較健康人、輕度認知障礙、阿茲海默症病人之藍斑核對比度差異

Date Issued
2025
Author(s)
謝欣恬
HSIEH, HSIN-TIEN
Advisor
蔡炳煇  
TSAI, PING-HUEI  
URI
https://handle.ncl.edu.tw/11296/pk8rpz
https://scholars.csmu.edu.tw/handle/123456789/7569
Abstract
根據衛福部 113 年統計,全國約 19 萬老年人患有阿茲海默症,然而目前臨床多以 CDR 與 MMSE 量表分數評估,缺乏較客觀且可量化的診斷工具。因此本實驗將以磁振造影T1 權重影像比較健康人、輕度任認知障礙患者與阿茲海默症病人腦中藍班核對比度之差異,並探討對比度與臨床量表分數、腦脊髓液中生理指標濃度之間的關聯性。 本實驗資料取自ADNI資料庫,選擇健康人、輕度認知障礙與阿茲海默症病人各24名,每組男性、女性各12人,共72位受試者。收集受試者之3T T1 MPRAGE 影像後,並於MATLAB平台手動圈選雙側藍斑核與橋腦作為感興趣區域,再分別以左右橋腦作為訊號強度正規化之參考區域,計算雙側藍斑核對比度。接著使用基於體素的型態學測量方法 (VBM) 比較受試者間在大腦型態學上的差異。最後使用 SPSS Statistics 29.0進行統計檢定,比較三組藍斑核對比度是否有差異,並分析對比度與臨床量表分數、腦脊髓液中生理指標濃度之間的相關性。 結果顯示,健康受試者之藍斑核對比度0.114±0.04,明顯高於輕度認知障礙組的0.087±0.02(p<0.001)與阿茲海默症病人的0.099±0.03 (p<0.05),而輕度認知障礙組與阿茲海默症病人之間則無顯著差異。在左右雙側對比度比較中,左側對比度明顯高於右側(0.105±0.035與0.095±0.028,p值=0.004),且不受組別影響。此外,三組之藍斑核對比度與腦脊髓液中Aβ42濃度(r=0.655,p值<0.001)、Aβ42/40比例呈現中度正相關(r=0.546,p值<0.001)。在VBM結果中發現,輕度認知障礙病人與阿茲海默症病人在內側顳葉、海馬迴等區域顯著萎縮,且多位於左側半腦 。 本研究初步證實在健康受試者之藍斑核對比度顯著高於輕度認知障礙與阿茲海默症病人,且藍斑核對比度也與腦脊髓液中類澱粉蛋白生理指標濃度呈現正相關,顯示在活體中,藍斑核神經元活性與類澱粉蛋白致病路徑有關連,或可作為非侵入式且無輻射的影像評估指標之一,提供更多神經退化相關資訊以供臨床醫師判讀。
According to Ministry of Health and Welfare report in 2024, approximately 190,000 elderly have been diagnosed as Alzheimer's disease (AD) in Taiwan. However, clinical assessments still rely on scales such as the Clinical Dementia Rating (CDR) and the Mini-Mental State Examination (MMSE), highlighting the need for more objective methods to diagnosis and quantify the severity of AD. Hence, this study aims to use T1-weighted MRI as a non-invasive tool to compare differences in locus coeruleus (LC) contrast among healthy controls, MCI patients and AD patients, and explore the relationships between LC contrast, clinical scales scores and CSF biomarkers levels.All of the data were obtained from the ADNI database. Total of 72 participants were selected, including 24 healthy controls, 24 MCI patients and 24 AD patients. Each group equally has 12 males and 12 females. Region of interest (ROI) of locus coeruleus (LC) and pons were manually delineated on 3T T1-MPRAGE images using MATLAB, and calculate bilateral LC contrast slice by slice. Additionally, Voxel-Based Morphometry (VBM) was applied to compare differences in brain morphology among three groups. Statistical analyses were conducted using SPSS Statistics 29.0 to compare LC contrast among groups and to examine its associations with clinical scale scores and CSF biomarker levels.According to the results, the LC contrast of healthy controls was significantly higher than that of MCI and AD patients (0.114±0.04,0.087±0.02 and 0.099±0.03 respectively, p value<0.001). In comparison of bilateral LC contrast, the left side showed significantly higher values than the right side (0.105±0.035 v.s.0.095±0.028, p value =0.004). Moreover, LC contrast shows a moderate positive correlation with CSF Aβ42 levels (r=0.655, p value<0.001) and the Aβ42/40 ratio (r=0.546, p value <0.001).As for VBM, it revealed that MCI and AD patients showed significant gray matter atrophy in medial temporal lobe and hippocampus, mostly in the left hemisphere.This study preliminary proves that healthy controls have higher Locus coeruleus (LC) contrast than MCI and AD patients. Moreover, LC contrast shows a positive correlation with CSF Aβ42 levels and the Aβ42/40ratio, indicating a potential link between LC neuronal activity and amyloid pathology in vivo. These findings suggest that LC contrast has the potential to become a non-invasive and quantitative imaging biomarker for evaluating neurodegenerative changes in clinical settings.
Subjects
藍斑核(Locus coeruleus)
輕度認知障礙(Mild Cognitive Impairment
MCI)
阿茲海默症(Alzheimer's disease,AD)
VBM(Voxel-Based Morphometry)
Locus coeruleus (LC)
Mild Cognitive Impairment (MCI)
Alzheimer's disease(AD)
Voxel-Based Morphometry (VBM)
Type
thesis
File(s)
No Thumbnail Available
Name

113CSMU0770005-002.pdf

Size

2.08 MB

Format

Adobe PDF

Checksum

(MD5):0f2bb6dee42a6093093f1c7884ac5794

Make it your own

DSpace-CRIS can be extensively configured to meet your needs. Decide which information need to be collected and available with fine-grained security. Start updating the theme to match your Institution's web identity.

Built with DSpace-CRIS software - Extension maintained and optimized by 4Science

  • Cookie settings
  • Privacy policy
  • End User Agreement
  • Send Feedback